Search

Postural control relies on three principal sensory systems: vision, vestibular and proprioceptive; that are affected by aging. When performing a cognitive task concomitantly with a motor task, those sensory impairments lead to even greater deleterious effects on balance. We aimed to study the effects of a sensory aid (a light touch) on a dual task paradigm and sought to understand the different responses on balance due to aging. Fifty healthy and highly physical active women were divided in two groups: young (N = 25, 24.2 ± 4.0 years) and older adults (N = 25, 67.3 ± 4.2 years). In a random and balanced order, all participants performed five tasks: Stroop test while seated (Seated); Stroop test while standing quiet (ST); Standing quiet (BL); Standing quiet with a haptic input (LT); and Stroop test with a haptic input while standing quiet (SL). In the Stroop test, older women committed more errors (50 vs 11 errors, p < 0.001) and had higher reaction time (1.001 ± 0.191 vs 0.699 ± 0.081 s, p < 0.001). The haptic input (LT) reduced all body sway parameters, in both groups, regardless the condition. This means that postural control under a dual task paradigm (ST) deleterious effect can be mitigated by a haptic input., (Copyright © 2022 Elsevier Inc. All rights reserved.)

Perception of external loads may be a central topic to understand adjustments to the mechanical demands during movement. Nevertheless, the association between the perceived and the real load received is still controversial. This study aimed to correlate vertical ground reaction force (vGRF) to the perception of impact in different regimens of stimulus application. Ten physically active men performed drop jumps from four different heights (0.20, 0.40, 0.60 and 0.80 m). A force plate measured the vGRF, while perception of impact was evaluated through Borg's Ratings of Perceived Exertion. Higher values of maximum vGRF (Fy&#95;max) and impulse of the first 50 ms (I&#95;50), and reduced time to reach Fy&#95;max indicate increased external forces as drop jump height raised. Perception of impact increased gradually with increasing jump height for I&#95;50. Fy&#95;max and I&#95;50 showed moderate to strong correlations to perceived load for 70% and 90% of participants, respectively. Higher and different intensity of stimulus facilitated the perception of impact, presenting moderate to strong correlations to kinetic parameters related to external load during landing from drop jump. Perception of higher impacts could be used as a surrogate to monitor 'real' impacts and possibly also for managing impact-related injury risk.

Objectives: To evaluate the effect of hydroalcoholic crude extract (HCE) from Chenopodium ambrosioides leaves on the development of type II collagen-induced arthritis (CIA) and on pro-inflammatory cytokine balance., Methods: Collagen-induced arthritis was induced in DBA1/J mice. On the 21st day, the mice were treated orally with HCE or methotrexate, daily. Six weeks after beginning the treatment, the following measures were determined: lymphoid organs cell numbers, percentage of blood cells, IL-6, IFN-γ, TNF-α and IL-17 serum concentrations, activity of hepatic and kidney glutathione S-transferase, hepatic 7-ethoxyresorufin-O-deethylase activity, bone density and histopathology., Key Findings: Treatment of CIA mice with HCE 5 mg/kg (HCE5) reduced the percentage of neutrophils and macrophages and the number of bone marrow cells and increased the lymphocyte numbers and the inguinal lymph node cellularity. This treatment inhibited the serum concentration of IL-6 and TNF-α, which may be related to the preservation of bone density and to the slight thickening of periarticular tissues, with minimal fibrosis and fibroblast proliferation in the joints. The CIA group presented advanced articular erosion and synovial hyperplasia. Phytochemical analysis showed mainly flavonols., Conclusions: HCE5 presented anti-arthritic potential and reduced IL-6 and TNF-α, which participate directly in the development and maintenance of the inflammatory process in rheumatoid arthritis., (© 2018 Royal Pharmaceutical Society.)